Peanut Allergy and the Early-Introduction Reversal

For about fifteen years, parents in several countries were told to keep peanut away from babies at risk of allergy. The advice was confident, it was official, and it was wrong — and in 2015 a single randomised trial showed it plainly. Infants who ate peanut protein regularly from the age of four to eleven months ended up with dramatically less peanut allergy than infants who avoided it, not more. This page covers what peanut allergy actually is, how a reaction happens and what to do about it, and the reversal in prevention advice that is one of the clearest examples in modern medicine of a plausible-sounding precaution making a problem worse. It also covers oral immunotherapy honestly — benefits and real risks — and why blanket school peanut bans have quietly fallen out of favour.

Table of Contents

  1. What Peanut Allergy Actually Is
  2. How Common It Is, and Who Gets It
  3. The Proteins: Ara h 2 and Why Reactions Are Severe
  4. Recognising a Reaction, and Anaphylaxis
  5. The Advice That Was Wrong
  6. The LEAP Trial and What It Showed
  7. What the Guidelines Say Now, and How It Is Done
  8. Thresholds: How Much Peanut It Takes
  9. Oral Immunotherapy, Honestly
  10. Peanut Oil, Labels and “May Contain”
  11. Schools: From Blanket Bans to Real Plans
  12. Living With It: The Practical List
  13. Key Research Papers
  14. Connections
  15. Featured Videos

What Peanut Allergy Actually Is

Peanut allergy is a mistake made by the immune system. In a person who is not allergic, peanut protein arrives in the gut, is broken up, and is treated as food — the immune system actively learns to ignore it, a process called oral tolerance. In a person who becomes allergic, that learning does not happen. Instead the immune system builds IgE antibodies against specific peanut proteins and parks them on the surface of mast cells and basophils, the body's chemical-release cells, which sit in the skin, gut, airway and blood vessel walls.

Nothing happens until the next exposure. Then peanut protein crosses-links two of those antibodies on a mast cell, the cell empties in seconds, and histamine, tryptase, prostaglandins and leukotrienes flood the tissue. Blood vessels leak, smooth muscle contracts, mucus is produced. That is what hives, vomiting, wheezing and throat swelling actually are — not the peanut damaging anything, but the body's own emergency chemistry released at the wrong moment.

Two things follow from this description and both matter practically. First, the reaction is fast, because it does not require the immune system to do anything new — the ammunition is already loaded. Most reactions begin within minutes and almost all within two hours. Second, the dose that triggers it can be tiny, because a mast cell does not care how much protein arrived, only whether enough antibodies got cross-linked.

Peanut allergy is also, unusually, mostly permanent. Milk and egg allergies are typically outgrown; peanut allergy is outgrown by roughly a fifth of affected children. That difference is part of why it dominates the food-allergy conversation despite milk allergy being more common in infancy.

Back to Table of Contents

How Common It Is, and Who Gets It

In the United States, the United Kingdom and Australia, peanut allergy affects on the order of one to two per cent of children. That figure is not a historical constant. Sicherer and colleagues ran the same telephone survey of US households in 1997, 2002 and 2008 and found self-reported peanut allergy in children rising across the three surveys — a genuine upward trend, not just better recognition, though better recognition is part of it. A large 2019 survey of US adults found convincing food allergy in around one in ten, with peanut the most commonly reported single food.

Risk is not evenly spread. The strongest predictor in infancy is severe eczema, especially eczema that starts early and is hard to control. Egg allergy is the second. The leading explanation for why is the dual-allergen-exposure hypothesis: an infant with a broken skin barrier meets peanut protein through inflamed skin — from household dust, from a carer's hands, from a kissed cheek — before ever meeting it in the gut. Exposure through damaged skin tends to teach the immune system to attack; exposure through the gut tends to teach it to tolerate. If that is right, then keeping peanut out of a baby's mouth while it is still landing on their skin is close to the worst possible combination, which is exactly what the old advice produced.

Family history matters less than most parents expect. Having an allergic sibling raises risk, but the majority of children who develop peanut allergy have no allergic sibling, and there is no useful genetic test.

Back to Table of Contents

The Proteins: Ara h 2 and Why Reactions Are Severe

Allergens are named after the organism they come from, so peanut allergens are Ara h — from Arachis hypogaea — followed by a number. The ones that matter clinically are Ara h 1, Ara h 2, Ara h 3 and Ara h 6.

The uncomfortable structural fact is that these proteins are built to survive. A seed's storage protein has to sit in a dry kernel for a season and then resist the seedling's own enzymes until it is needed, so it is compact, cross-linked and stable. Roasting at 175 °C does not destroy it — dry roasting appears if anything to make some peanut allergens more reactive by altering their surface chemistry. Stomach acid and digestive enzymes do not destroy it either, which means intact allergen reaches the gut wall where the mast cells are. Compare a fruit allergy caused by a fragile pollen-related protein, where a cooked apple is fine and a raw one is not: peanut offers no such escape.

One consequence worth stating clearly, because it is a common misunderstanding: peanut allergy and tree-nut allergy are separate conditions. Peanut is a legume; its proteins are legume storage proteins, closer to those of lentils and beans than to those of almonds. Many peanut-allergic people eat tree nuts safely. Many do have both allergies — but that is co-occurrence, and only testing and a clinician's judgement can tell one from the other in an individual.

Back to Table of Contents

Recognising a Reaction, and Anaphylaxis

Reactions run along a spectrum, and the same person does not always react the same way twice.

Epinephrine (adrenaline) is the treatment for anaphylaxis, and it is the only treatment that reverses it. It is given into the outer thigh muscle, it works within minutes, and delay is the single factor most consistently associated with fatal outcomes. Bock and colleagues reviewed food-anaphylaxis fatalities reported to a US registry and found peanut and tree nuts responsible for the majority; delayed or absent epinephrine was a recurring feature. Antihistamines treat hives. They do not open an airway and they do not restore blood pressure. Reaching for one instead of the auto-injector has cost lives, and a child who has been given an antihistamine and looks briefly calmer can deteriorate on the way to hospital.

Practical points that matter more than they sound:

  1. Give epinephrine early rather than waiting to be sure. The harm from an unnecessary dose is a racing heart and shakiness for twenty minutes. The harm from a late dose can be permanent.
  2. Call emergency services after giving it, every time, and lie the person flat with legs raised unless they are vomiting or struggling to breathe. Standing a collapsing person up can be fatal.
  3. Carry two injectors. Reactions can rebound or need a second dose before help arrives.
  4. Asthma raises the stakes. Poorly controlled asthma is one of the strongest risk factors for a severe food-anaphylaxis outcome, so keeping asthma well controlled is part of managing peanut allergy.

Full detail on recognition and emergency management is on the anaphylaxis page; food allergy covers diagnosis and labelling more broadly.

Back to Table of Contents

The Advice That Was Wrong

In 2000 the American Academy of Pediatrics advised that infants at high risk of allergy should not be given peanut until the age of three. Similar advice appeared in the United Kingdom in 1998. The reasoning was intuitive: an immature immune system meeting a potent allergen early might be sensitised by it, so wait until the child is more robust. Nobody had tested the idea in a randomised trial. It was a precaution, and precautions feel free.

Over the following decade peanut allergy rates in those countries went up, not down. That alone proved nothing — the advice might have been working against an even stronger trend. But a striking observation published in 2008 made the picture harder to explain away. Du Toit and colleagues compared Jewish schoolchildren in the United Kingdom with Jewish schoolchildren in Israel, populations with similar ancestry. Peanut allergy was around ten times more common in the UK children. The most conspicuous difference in early diet was Bamba, a puffed maize-and-peanut snack that Israeli infants eat from a very young age, in a country where median peanut consumption in infancy was substantial and in the UK it was essentially nil.

That was an observational finding and could have had a dozen explanations. What it did was make the question testable, and worth the expense of testing.

Back to Table of Contents

The LEAP Trial and What It Showed

LEAP — Learning Early About Peanut Allergy — enrolled 640 infants between four and eleven months old who had severe eczema, egg allergy, or both: precisely the group the old guidance told to avoid peanut. Every infant was skin-prick tested first. Those with a very large wheal, indicating established allergy, were excluded. The rest were randomly assigned either to eat at least 6 grams of peanut protein a week, spread across three or more meals, or to avoid peanut entirely until they turned five. At five, everyone was formally food-challenged.

The result, published in the New England Journal of Medicine in 2015, was not subtle. Among the children who had shown no sensitisation at the start, peanut allergy at age five was 13.7 per cent in the avoidance group and 1.9 per cent in the consumption group. Among the children who had started with mild sensitisation — a small but measurable skin-test response — it was 35.3 per cent with avoidance and 10.6 per cent with consumption. Both differences were large and highly significant. Overall the trial reported a relative reduction of roughly 80 per cent.

Two obvious objections were then answered by follow-up work:

A second trial, EAT, took a different population — ordinary breastfed infants from the general population, not a high-risk group — and introduced six allergenic foods from three months of age. In the analysis of children who actually managed the assigned regimen, early introduction reduced food allergy, with the effect for peanut the clearest of the six. The main intention-to-treat analysis did not reach significance, largely because feeding six allergenic foods to three-month-olds on schedule turned out to be very hard for families. That honest limitation is worth stating: EAT supports LEAP, it does not independently replicate it.

Back to Table of Contents

What the Guidelines Say Now, and How It Is Done

In 2017 an expert panel sponsored by the US National Institute of Allergy and Infectious Diseases published addendum guidelines that reversed the old advice outright. In outline:

  1. Infants with severe eczema, egg allergy, or both should have peanut-containing food introduced around 4 to 6 months, after evaluation — specific IgE testing, skin-prick testing, or a supervised feeding, depending on the setting.
  2. Infants with mild to moderate eczema should have peanut introduced around 6 months, in line with other solids, without special testing.
  3. Infants with no eczema and no food allergy should have peanut introduced freely, with the family diet, whenever solids begin.

Guidance elsewhere has moved in the same direction, with local variation in whether pre-testing is recommended and at what age. Where advice differs, it differs on the details of screening, not on the central point that delay is not protective.

The two safety points that must not get lost.

First, high-risk infants should be assessed before peanut is introduced at home. That is how LEAP was run — every infant was tested and the already-allergic were excluded — and it is what the guidelines say. Early introduction is not a reason to feed peanut to a baby who has already reacted to something, or who has severe uncontrolled eczema, without asking first.

Second, whole and chopped peanuts are a serious choking hazard for children under about four and must never be given. A whole peanut is exactly the wrong size and shape for a small airway. Early introduction is done with:

Read the label for protein content: the LEAP dose was about 2 grams of peanut protein three times a week, which is roughly two level teaspoons of peanut butter per feed. Start with a smear on the lip or a tiny taste, wait, and offer the rest if nothing happens. Do it in the morning, at home, when someone can watch the baby for a couple of hours — not at bedtime and not in the car.

Once started, keep going. Regular exposure is what maintains tolerance while it is being built. A few weeks of peanut and then nothing for six months is not what any of the trials tested.

Back to Table of Contents

Thresholds: How Much Peanut It Takes

Families always want a number, and the honest answer has two halves.

The first half: there is no dose that is safe for everyone. Taylor and colleagues pooled published food-challenge data from peanut-allergic individuals and modelled the distribution of eliciting doses. The distribution has a long, thin left tail — a small minority react to amounts measured in fractions of a milligram of peanut protein, far less than a crumb.

The second half: most allergic people are not at that end. The great majority need considerably more than a trace, which is why accidental exposures far more often produce hives and vomiting than collapse, and why the terrifying stories tend to involve someone eating a real portion of something they did not know contained peanut, not touching a doorknob. Airborne reactions to peanut are genuinely rare outside settings like an enclosed space where peanuts are being roasted or shelled in quantity; skin contact usually causes local hives rather than anaphylaxis.

Regulators and food manufacturers use this modelled distribution to set reference doses for precautionary labelling — the level below which a manufacturer may reasonably decide a “may contain” warning is not warranted. Knowing an individual's own threshold requires a supervised oral food challenge, which is the only test that answers the question directly and is done in a hospital setting for good reason.

The practical upshot is not reassurance and it is not panic. It is that avoidance should be aimed at real ingestion — labels, restaurant meals, shared food — rather than at the environment, and that emergency medication should always be present because an individual's threshold is not fixed. Exercise, illness, alcohol and poorly controlled asthma all appear to lower it.

Back to Table of Contents

Oral Immunotherapy, Honestly

Oral immunotherapy takes the thing that causes the reaction and gives it deliberately, starting at a dose far below the person's threshold and escalating over months under medical supervision, until they can tolerate an amount that would previously have caused a reaction.

What it achieves. The PALISADE trial tested a standardised, characterised peanut protein product in children and adolescents. Among the participants aged 4 to 17 who completed the protocol, a majority of those on active treatment could tolerate a substantially higher challenge dose at the end than at the start, compared with a small minority on placebo. A product based on that work was approved by the US Food and Drug Administration in 2020 for children aged 4 to 17. The IMPACT trial then tested peanut oral immunotherapy in children aged one to three, and found both desensitisation and, in a meaningful fraction, remission that persisted through a period off treatment — suggesting that the younger the immune system, the more it can be re-taught.

What it does not achieve. It is not a cure and it does not mean eating peanut freely. The goal is protection against accidental exposure — turning a cracker with hidden peanut from an emergency into a non-event.

The real cost, which deserves to be stated plainly. Chu and colleagues published a systematic review and meta-analysis of peanut oral immunotherapy trials in the Lancet in 2019 with an uncomfortable finding: while treatment reliably increased the amount of peanut tolerated at a supervised challenge, participants receiving oral immunotherapy experienced more anaphylaxis and more epinephrine use during the trials than those avoiding peanut. In other words the therapy trades a rare risk from accidental exposure for a more frequent, more predictable risk from the treatment itself. Some families judge that trade worth making, particularly for a young child or a very low-threshold one. Others reasonably do not. A meaningful minority drop out because of persistent stomach symptoms, and eosinophilic oesophagitis is a recognised complication.

Rules that apply without exception: it is done under specialist supervision; doses are taken with food and never on an empty stomach; vigorous exercise, hot baths and illness require dose adjustment; and it is never, ever attempted at home with supermarket peanut butter. The dose escalation is precisely the part that requires a clinic with epinephrine on the trolley.

Back to Table of Contents

Peanut Oil, Labels and “May Contain”

Refined peanut oil. Hourihane and colleagues ran a double-blind, crossover challenge study of peanut oils in peanut-allergic subjects and reported that highly refined peanut oil did not provoke reactions, whereas crude, unrefined oil did in some participants. The reason is straightforward: refining removes the protein, and protein is the allergen. This is why highly refined peanut oil is generally exempt from allergen declaration in several jurisdictions. Cold-pressed, expeller-pressed, gourmet, aromatic and “roasted” peanut oils retain protein and should be avoided. Anyone with a history of anaphylaxis should settle the question with their own allergist rather than relying on a general statement, and a restaurant that says it fries in peanut oil is usually not in a position to tell you which grade.

Labels. Peanut is a declared major allergen in the United States, the European Union, the United Kingdom, Canada and Australia, so it must appear in the ingredient list of a packaged food by name. That part is reliable. The unreliable part is precautionary labelling — “may contain peanuts”, “made in a facility that also processes peanuts”, “not suitable for nut allergy sufferers”. These phrases are largely voluntary and unstandardised; they do not correspond to measured amounts, and there is no consistent relationship between the wording used and the actual risk. The general advice from allergy organisations is to avoid products carrying them, while recognising that the honest reason is a lack of information rather than a demonstrated hazard.

Where peanut hides. Satay and other peanut sauces; West African groundnut stews; mole; some chilis and gravies thickened with peanut; marzipan substitutes; egg rolls sealed with peanut butter; vegetarian burgers and meat substitutes; baked goods and ice creams made on shared lines; some pet foods and bird feed handled in the kitchen. The two situations that most often catch people out are unfamiliar cuisines where peanut is a base ingredient rather than a garnish, and food handed over informally at parties, bake sales and other people's houses.

Back to Table of Contents

Schools: From Blanket Bans to Real Plans

The blanket peanut ban — no peanut products anywhere on the premises — was a common response through the 2000s, and it has been steadily replaced. The reasoning behind the shift is worth understanding, because it is not a downgrade of the risk.

A whole-school ban is very hard to enforce and impossible to verify. It cannot control what is in a lunchbox, and it creates a false confidence that the environment is clean, which is the single most dangerous belief a school can hold. It also does nothing about the other foods children are allergic to; a school with a peanut ban and a child with a sesame or milk allergy has solved one problem and left the rest. And it displaces attention from the measures that demonstrably work.

Approaches now generally recommended focus on those measures instead:

The one-line summary a parent can use with a school: the plan is what protects my child, not the ban.

Back to Table of Contents

Living With It: The Practical List

Peanut allergy is a serious diagnosis, and it is also a manageable one. Most people with it live ordinary lives, and the anxiety is frequently heavier than the medical burden. What makes the difference is being systematic about a few things and relaxed about the rest.

  1. Get a proper diagnosis, including component testing. A positive whole-peanut IgE without a history of reaction is not the same as an allergy. Ara h 2 testing and, where indicated, a supervised food challenge can end an avoidance regime that was never necessary. This happens more often than people expect.
  2. Two epinephrine auto-injectors, always, on the person. Not in the car, not in a bag left at the table. Check expiry dates twice a year on a date you will remember.
  3. Practise with a trainer device and make sure every carer, grandparent, babysitter and coach has done the same. Adolescents should carry and be able to use their own.
  4. Keep asthma well controlled. This is the single highest-value background task.
  5. Read every label every time. Recipes change without announcement, and a product that was safe last month may not be this month.
  6. Have a script for restaurants — state the allergy at booking and again at the table, ask about the fryer and about sauces, and be prepared to walk out. Chef cards in the local language are genuinely useful when travelling.
  7. Teach a child the words, not the fear. “I am allergic to peanuts, I need to check” is a sentence a five-year-old can own. Children who feel competent about their allergy do better than children who feel fragile.
  8. Talk about the adolescent risk directly. Teenagers and young adults are over-represented in fatal food-anaphylaxis reports, usually through a combination of not carrying the injector, eating away from home and not wanting to make a fuss.
  9. Ask about oral immunotherapy if it interests you, with the trade-off above in front of you, and ask specifically about your own child's age — the toddler data are the most encouraging.
  10. If there is a new baby in the family, do not repeat the old mistake. Talk to a clinician about early introduction rather than assuming a sibling's allergy means avoidance.

Back to Table of Contents

Key Research Papers

  1. Du Toit G, Roberts G, Sayre PH, Bahnson HT, Radulovic S, Santos AF, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. New England Journal of Medicine. 2015;372(9):803-813. — doi:10.1056/NEJMoa1414850
  2. Du Toit G, Sayre PH, Roberts G, Sever ML, Lawson K, Bahnson HT, et al. Effect of avoidance on peanut allergy after early peanut consumption (LEAP-On). New England Journal of Medicine. 2016;374(15):1435-1443. — doi:10.1056/NEJMoa1514209
  3. Du Toit G, Huffaker MF, Radulovic S, Feeney M, Fisher HR, Byron M, et al. Follow-up to adolescence after early peanut introduction for allergy prevention (LEAP-Trio). NEJM Evidence. 2024;3(6). — doi:10.1056/evidoa2300311
  4. Perkin MR, Logan K, Tseng A, Raji B, Ayis S, Peacock J, et al. Randomized trial of introduction of allergenic foods in breast-fed infants (EAT). New England Journal of Medicine. 2016;374(18):1733-1743. — doi:10.1056/NEJMoa1514210
  5. Du Toit G, Katz Y, Sasieni P, Mesher D, Maleki SJ, Fisher HR, et al. Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy. Journal of Allergy and Clinical Immunology. 2008;122(5):984-991. — doi:10.1016/j.jaci.2008.08.039
  6. Togias A, Cooper SF, Acebal ML, Assa'ad A, Baker JR, Beck LA, et al. Addendum guidelines for the prevention of peanut allergy in the United States: report of the National Institute of Allergy and Infectious Diseases-sponsored expert panel. Journal of Allergy and Clinical Immunology. 2017;139(1):29-44. — doi:10.1016/j.jaci.2016.10.010
  7. The PALISADE Group of Clinical Investigators. AR101 oral immunotherapy for peanut allergy. New England Journal of Medicine. 2018;379(21):1991-2001. — doi:10.1056/NEJMoa1812856
  8. Chu DK, Wood RA, French S, Fiocchi A, Jordana M, Waserman S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. The Lancet. 2019;393(10187):2222-2232. — doi:10.1016/S0140-6736(19)30420-9
  9. Jones SM, Kim EH, Nadeau KC, Nowak-Wegrzyn A, Wood RA, Sampson HA, et al. Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (IMPACT). The Lancet. 2022;399(10322):359-371. — doi:10.1016/S0140-6736(21)02390-4
  10. Taylor SL, Crevel RW, Sheffield D, Kabourek J, Baumert J. Threshold dose for peanut: risk characterization based upon published results from challenges of peanut-allergic individuals. Food and Chemical Toxicology. 2009;47(6):1198-1204. — doi:10.1016/j.fct.2009.02.011
  11. Hourihane JO, Bedwani SJ, Dean TP, Warner JO. Randomised, double blind, crossover challenge study of allergenicity of peanut oils in subjects allergic to peanuts. BMJ. 1997;314(7087):1084. — doi:10.1136/bmj.314.7087.1084
  12. Gupta RS, Warren CM, Smith BM, Jiang J, Blumenstock JA, Davis MM, et al. Prevalence and severity of food allergies among US adults. JAMA Network Open. 2019;2(1):e185630. — doi:10.1001/jamanetworkopen.2018.5630
  13. Sicherer SH, Muñoz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. Journal of Allergy and Clinical Immunology. 2010;125(6):1322-1326. — doi:10.1016/j.jaci.2010.03.029
  14. Bock SA, Muñoz-Furlong A, Sampson HA. Fatalities due to anaphylactic reactions to foods. Journal of Allergy and Clinical Immunology. 2001;107(1):191-193. — doi:10.1067/mai.2001.112031

Live PubMed Searches

  1. PubMed: peanut allergy early introduction prevention
  2. PubMed: Ara h 2 component-resolved diagnosis
  3. PubMed: peanut oral immunotherapy safety
  4. PubMed: food allergy school policy and stock epinephrine

Back to Table of Contents

Connections

Back to Table of Contents